Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Journal of Immunology Research
Volume 2017, Article ID 8415205, 11 pages
https://doi.org/10.1155/2017/8415205
Review Article

The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation

1Division of Transplant Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
2Xenotransplantation Program, Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL, USA

Correspondence should be addressed to Burcin Ekser; ude.iupui@reskeb

Received 17 July 2017; Accepted 17 September 2017; Published 11 October 2017

Academic Editor: Vered Padler-Karavani

Copyright © 2017 Kannan P. Samy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Ekser, M. Ezzelarab, H. Hara et al., “Clinical xenotransplantation: the next medical revolution?” Lancet, vol. 379, no. 9816, pp. 672–683, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Ekser, D. K. Cooper, and A. J. Tector, “The need for xenotransplantation as a source of organs and cells for clinical transplantation,” International Journal of Surgery, vol. 23, Part B, pp. 199–204, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Ekser, A. J. Tector, and D. K. Cooper, “Progress toward clinical xenotransplantation,” International Journal of Surgery, vol. 23, Part B, pp. 197-198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. D. K. Cooper, B. Ekser, and A. J. Tector, “Immunobiological barriers to xenotransplantation,” International Journal of Surgery, vol. 23, Part B, pp. 211–216, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. D. K. Cooper, M. B. Ezzelarab, H. Hara et al., “The pathobiology of pig-to-primate xenotransplantation: a historical review,” Xenotransplantation, vol. 23, no. 2, pp. 83–105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. D. K. Cooper, “Depletion of natural antibodies in non-human primates--a step towards successful discordant xenografting in humans,” Clinical Transplantation, vol. 6, no. 3, Part 1, pp. 178–183, 1992. View at Google Scholar
  7. D. K. Cooper, A. H. Good, E. Koren et al., “Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man,” Transplant Immunology, vol. 1, no. 3, pp. 198–205, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. A. H. Good, D. K. Cooper, A. J. Malcolm et al., “Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans,” Transplantation Proceedings, vol. 24, no. 2, pp. 559–562, 1992. View at Google Scholar
  9. D. K. Cooper, B. Ekser, J. Ramsoondar, C. Phelps, and D. Ayares, “The role of genetically engineered pigs in xenotransplantation research,” The Journal of Pathology, vol. 238, no. 2, pp. 288–299, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Phelps, C. Koike, T. D. Vaught et al., “Production of α1,3-galactosyltransferase-deficient pigs,” Science, vol. 299, no. 5605, pp. 411–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Butler, J. M. Ladowski, G. R. Martens, M. Tector, and A. J. Tector, “Recent advances in genome editing and creation of genetically modified pigs,” International Journal of Surgery, vol. 23, Part B, pp. 217–222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. D. K. Cooper, H. Hara, M. Ezzelarab et al., “The potential of genetically-engineered pigs in providing an alternative source of organs and cells for transplantation,” Journal of Biomedical Research, vol. 27, no. 4, pp. 249–253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Butler and A. J. Tector, “CRISPR genome-editing: a medical revolution,” The Journal of Thoracic and Cardiovascular Surgery, vol. 153, no. 2, pp. 488–491, 2017. View at Publisher · View at Google Scholar
  14. J. R. Butler, G. R. Martens, J. L. Estrada et al., “Silencing porcine genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation,” Transgenic Research, vol. 25, no. 5, pp. 751–759, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. P. F. Halloran, “Immunosuppressive drugs for kidney transplantation,” The New England Journal of Medicine, vol. 351, no. 26, pp. 2715–2729, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. Wiseman, “Immunosuppressive medications,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 2, pp. 332–343, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Ford, A. B. Adams, and T. C. Pearson, “Targeting co-stimulatory pathways: transplantation and autoimmunity,” Nature Reviews Nephrology, vol. 10, no. 1, pp. 14–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Buhler, S. Deng, J. O'Neil et al., “Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade,” Xenotransplantation, vol. 9, no. 1, pp. 3–13, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. D. J. van der Windt, R. Bottino, A. Casu et al., “Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets,” American Journal of Transplantation, vol. 9, no. 12, pp. 2716–2726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Thompson, I. R. Badell, M. Lowe et al., “Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function,” American Journal of Transplantation, vol. 11, no. 12, pp. 2593–2602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Thompson, K. Cardona, M. Russell et al., “CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates,” American Journal of Transplantation, vol. 11, no. 5, pp. 947–957, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Higginbotham, D. Mathews, C. A. Breeden et al., “Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model,” Xenotransplantation, vol. 22, no. 3, pp. 221–230, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Iwase, H. Liu, M. Wijkstrom et al., “Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date,” Xenotransplantation, vol. 22, no. 4, pp. 302–309, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Shah, M. S. Patel, N. Elias et al., “Prolonged survival following pig-to-primate liver xenotransplantation utilizing exogenous coagulation factors and costimulation blockade,” American Journal of Transplantation, vol. 17, no. 8, pp. 2178–2185, 2017. View at Publisher · View at Google Scholar
  25. H. Iwase, H. Hara, M. Ezzelarab et al., “Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts,” Xenotransplantation, vol. 24, no. 2, article e12293, 2017. View at Publisher · View at Google Scholar
  26. T. Wekerle and J. M. Grinyo, “Belatacept: from rational design to clinical application,” Transplant International, vol. 25, no. 2, pp. 139–150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Esensten, Y. A. Helou, G. Chopra, A. Weiss, and J. A. Bluestone, “CD28 costimulation: from mechanism to therapy,” Immunity, vol. 44, no. 5, pp. 973–988, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. C. P. Larsen, T. C. Pearson, A. B. Adams et al., “Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties,” American Journal of Transplantation, vol. 5, no. 3, pp. 443–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Vincenti, C. Larsen, A. Durrbach et al., “Costimulation blockade with belatacept in renal transplantation,” The New England Journal of Medicine, vol. 353, no. 8, pp. 770–781, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. B. J. Hering, D. K. Cooper, E. Cozzi et al., “The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-- executive summary,” Xenotransplantation, vol. 16, no. 4, pp. 196–202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. K. C. Cooper, M. Wijkstrom, S. Hariharan et al., “Selection of patients for initial clinical trials of solid organ xenotransplantation,” Transplantation, vol. 101, no. 7, pp. 1551–1558, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. A. H. Sharpe and A. K. Abbas, “T-cell costimulation—biology, therapeutic potential, and challenges,” New England Journal of Medicine, vol. 355, no. 10, pp. 973–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. H. Sharpe, “Mechanisms of costimulation,” Immunological Reviews, vol. 229, no. 1, pp. 5–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Mou, J. Espinosa, D. J. Lo, and A. D. Kirk, “CD28 negative T cells: is their loss our gain?” American Journal of Transplantation, vol. 14, no. 11, pp. 2460–2466, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Medzhitov and C. A. Janeway Jr., “Innate immune recognition and control of adaptive immune responses,” Seminars in Immunology, vol. 10, no. 5, pp. 351–353, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. D. L. Sprague, J. M. Sowa, B. D. Elzey, and T. L. Ratliff, “The role of platelet CD154 in the modulation in adaptive immunity,” Immunologic Research, vol. 39, no. 1–3, pp. 185–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Y. Ma and E. A. Clark, “The role of CD40 and CD154/CD40L in dendritic cells,” Seminars in Immunology, vol. 21, no. 5, pp. 265–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Cerutti, I. Puga, and M. Cols, “Innate control of B cell responses,” Trends in Immunology, vol. 32, no. 5, pp. 202–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. D. J. Wikenheiser and J. S. Stumhofer, “ICOS co-stimulation: friend or foe?” Frontiers in Immunology, vol. 7, p. 304, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. J. R. Espinosa, K. P. Samy, and A. D. Kirk, “Memory T cells in organ transplantation: progress and challenges,” Nature Reviews Nephrology, vol. 12, no. 6, pp. 339–347, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. D. J. Anderson, D. J. Lo, F. Leopardi et al., “Anti-LFA-1 therapy in a nonhuman primate renal transplant model of costimulation blockade resistant rejection,” American Journal of Transplantation, vol. 16, no. 5, pp. 1456–1464, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. M. R. Nicolls and R. G. Gill, “LFA-1 (CD11a) as a therapeutic target,” American Journal of Transplantation, vol. 6, no. 1, pp. 27–36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. K. P. Samy, D. J. Anderson, D. J. Lo et al., “Selective targeting of high-affinity LFA-1 does not augment costimulation blockade in a nonhuman primate renal transplantation model,” American Journal of Transplantation, vol. 17, no. 5, pp. 1193–1203, 2017. View at Publisher · View at Google Scholar
  44. A. D. Kirk, D. M. Harlan, N. N. Armstrong et al., “CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 16, pp. 8789–8794, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. T. A. Weaver, A. H. Charafeddine, A. Agarwal et al., “Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates,” Nature Medicine, vol. 15, no. 7, pp. 746–749, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. I. R. Badell, M. C. Russell, K. Cardona et al., “CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8,” American Journal of Transplantation, vol. 12, no. 7, pp. 1918–1923, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. D. J. Lo, D. J. Anderson, T. A. Weaver et al., “Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion,” American Journal of Transplantation, vol. 13, no. 2, pp. 320–328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. C. Lowe, I. R. Badell, A. P. Turner et al., “Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy,” American Journal of Transplantation, vol. 13, no. 2, pp. 312–319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. A. M. Freitas, K. P. Samy, A. B. Farris et al., “Studies introducing costimulation blockade for vascularized composite allografts in nonhuman primates,” American Journal of Transplantation, vol. 15, no. 8, pp. 2240–2249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Lo, D. J. Anderson, M. Song et al., “A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation,” American Journal of Transplantation, vol. 15, no. 4, pp. 984–992, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. A. D. Kirk, L. C. Burkly, D. S. Batty et al., “Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates,” Nature Medicine, vol. 5, no. 6, pp. 686–693, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Espinosa, F. Herr, G. Tharp et al., “CD57+ CD4 T cells underlie belatacept-resistant allograft rejection,” American Journal of Transplantation, vol. 16, no. 4, pp. 1102–1112, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Vivot, A. Langlois, N. Jeandidier et al., “Instant blood-mediated inflammatory reaction during islet transplantation: the role of Toll-like receptors signaling pathways,” Transplantation Proceedings, vol. 43, no. 9, pp. 3192–3194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. I. R. Badell, M. C. Russell, P. W. Thompson et al., “LFA-1-specific therapy prolongs allograft survival in rhesus macaques,” The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4520–4531, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Dobbels, S. Wong, Y. Min, J. Sam, and A. Kalsekar, “Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials,” Transplantation, vol. 98, no. 9, pp. 960–968, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Durrbach, J. M. Pestana, T. Pearson et al., “A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study),” American Journal of Transplantation, vol. 10, no. 3, pp. 547–557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. C. P. Larsen, J. Grinyo, J. Medina-Pestana et al., “Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies,” Transplantation, vol. 90, no. 12, pp. 1528–1535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Vincenti, B. Charpentier, Y. Vanrenterghem et al., “A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study),” American Journal of Transplantation, vol. 10, no. 3, pp. 535–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Rostaing, F. Vincenti, J. Grinyo et al., “Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study,” American Journal of Transplantation, vol. 13, no. 11, pp. 2875–2883, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Krummey, J. A. Cheeseman, J. A. Conger et al., “High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept,” American Journal of Transplantation, vol. 14, no. 3, pp. 607–614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. D. V. Mathews, W. C. Wakwe, S. C. Kim et al., “Belatacept resistant rejection is associated with CD28+ memory CD8 T cells,” American Journal of Transplantation, vol. 17, no. 9, pp. 2285–2299, 2017. View at Publisher · View at Google Scholar
  62. M. Cortes-Cerisuelo, S. J. Laurie, D. V. Mathews et al., “Increased pre-transplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients,” American Journal of Transplantation, vol. 17, no. 9, pp. 2350–2362, 2017. View at Publisher · View at Google Scholar
  63. A. D. Kirk, A. Guasch, H. Xu et al., “Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors,” American Journal of Transplantation, vol. 14, no. 5, pp. 1142–1151, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Ferguson, J. Grinyo, F. Vincenti et al., “Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients,” American Journal of Transplantation, vol. 11, no. 1, pp. 66–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Gupta, A. Regmi, D. Kumar et al., “Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction,” American Journal of Transplantation, vol. 15, no. 10, pp. 2726–2731, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. C. L. Law and I. S. Grewal, “Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges,” Advances in Experimental Medicine and Biology, vol. 647, pp. 8–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. D. P. Inwald, A. McDowall, M. J. Peters, R. E. Callard, and N. J. Klein, “CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation,” Circulation Research, vol. 92, no. 9, pp. 1041–1048, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Knosalla, B. Gollackner, and D. K. Cooper, “Anti-CD154 monoclonal antibody and thromboembolism revisted,” Transplantation, vol. 74, no. 3, pp. 416-417, 2002. View at Publisher · View at Google Scholar
  69. S. C. Kim, W. Wakwe, L. B. Higginbotham et al., “Fc-silent anti-CD154 domain antibody effectively prevents nonhuman primate renal allograft rejection,” American Journal of Transplantation, vol. 17, no. 5, pp. 1182–1192, 2017. View at Publisher · View at Google Scholar
  70. S. Oshima, E. E. Karrer, Y. Kawato et al., “The effect of ASP2409, a novel CD86-selective variant of CTLA4-Ig, on renal allograft rejection in nonhuman primates,” Transplantation, vol. 100, no. 12, pp. 2611–2620, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Poirier, G. Blancho, M. Hiance et al., “First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28,” Journal of Immunology, vol. 197, no. 12, pp. 4593–4602, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Song, A. Ma, H. Dun et al., “ASP2409, a next-generation CTLA4-Ig, versus belatacept in renal allograft survival in cynomolgus monkeys,” American Journal of Transplantation, vol. 17, no. 3, pp. 635–645, 2017. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Cozzi, F. Bhatti, M. Schmoeckel et al., “Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts,” Transplantation, vol. 70, no. 1, pp. 15–21, 2000. View at Google Scholar
  74. L. Buhler, M. Awwad, M. Basker et al., “High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response,” Transplantation, vol. 69, no. 11, pp. 2296–2304, 2000. View at Publisher · View at Google Scholar
  75. K. Yamada, K. Yazawa, A. Shimizu et al., “Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue,” Nature Medicine, vol. 11, no. 1, pp. 32–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Kim, L. Higginbotham, D. Mathews et al., “CD4 depletion is necessary and sufficient for long-term nonhuman primate xenotransplant survival,” American Journal of Transplantation, vol. 17, Supplement 3, pp. 374–374, 2017. View at Google Scholar
  77. H. Iwase, B. Ekser, V. Satyananda et al., “Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs,” Transplant Immunology, vol. 32, no. 2, pp. 99–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. M. M. Mohiuddin, A. K. Singh, P. C. Corcoran et al., “Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft,” Nature Communications, vol. 7, article 11138, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Thompson, I. R. Badell, M. Lowe et al., “Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival,” American Journal of Transplantation, vol. 12, no. 7, pp. 1765–1775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. C. J. Phelps, S. F. Ball, T. D. Vaught et al., “Production and characterization of transgenic pigs expressing porcine CTLA4-Ig,” Xenotransplantation, vol. 16, no. 6, pp. 477–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Klymiuk, L. van Buerck, A. Bahr et al., “Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice,” Diabetes, vol. 61, no. 6, pp. 1527–1532, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. D. G. Wheeler, M. E. Joseph, S. D. Mahamud et al., “Transgenic swine: expression of human CD39 protects against myocardial injury,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 5, pp. 958–961, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Hara, W. Witt, T. Crossley et al., “Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status,” Immunology, vol. 140, no. 1, pp. 39–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. Z. Liu, W. Hu, T. He et al., “Pig-to-primate islet xenotransplantation: past, present, and future,” Cell Transplantation, vol. 26, no. 6, pp. 925–947, 2017. View at Publisher · View at Google Scholar
  85. B. Ekser, R. Bottino, and D. K. Cooper, “Clinical islet xenotransplantation: a step forward,” eBioMedicine, vol. 12, pp. 22-23, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Buhler, M. Basker, I. P. Alwayn et al., “Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates,” Transplantation, vol. 70, no. 9, pp. 1323–1331, 2000. View at Publisher · View at Google Scholar
  87. S. L. Houser, K. Kuwaki, C. Knosalla et al., “Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons,” Xenotransplantation, vol. 11, no. 5, pp. 416–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. F. J. Dor, K. Kuwaki, Y. L. Tseng et al., “Potential of aspirin to inhibit thrombotic microangiopathy in α1,3-galactosyltransferase gene-knockout pig hearts after transplantation in baboons,” Transplantation Proceedings, vol. 37, no. 1, pp. 489-490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Kuwaki, Y. L. Tseng, F. J. Dor et al., “Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience,” Nature Medicine, vol. 11, no. 1, pp. 29–31, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. G. Wu, S. Pfeiffer, C. Schroder et al., “Co-stimulation blockade targeting CD154 and CD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft,” Xenotransplantation, vol. 12, no. 3, pp. 197–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. G. Wu, S. Pfeiffer, C. Schroder et al., “Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes,” Xenotransplantation, vol. 14, no. 1, pp. 34–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Ezzelarab, B. Garcia, A. Azimzadeh et al., “The innate immune response and activation of coagulation in α1,3-galactosyltransferase gene-knockout xenograft recipients,” Transplantation, vol. 87, no. 6, pp. 805–812, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. M. M. Mohiuddin, P. C. Corcoran, A. K. Singh et al., “B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months,” American Journal of Transplantation, vol. 12, no. 3, pp. 763–771, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Kim, H. K. Chee, J. Yang et al., “Outcomes of alpha 1,3-GT-knockout porcine heart transplants into a preclinical nonhuman primate model,” Transplantation Proceedings, vol. 45, no. 8, pp. 3085–3091, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. M. B. Ezzelarab, B. Ekser, A. Azimzadeh et al., “Systemic inflammation in xenograft recipients precedes activation of coagulation,” Xenotransplantation, vol. 22, no. 1, pp. 32–47, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Iwase, B. Ekser, V. Satyananda et al., “Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens,” Xenotransplantation, vol. 22, no. 3, pp. 211–220, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Buhler, K. Yamada, H. Kitamura et al., “Pig kidney transplantation in baboons: anti-Gal(alpha)1-3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation,” Transplantation, vol. 72, no. 11, pp. 1743–1752, 2001. View at Publisher · View at Google Scholar
  98. R. N. Barth, S. Yamamoto, J. C. LaMattina et al., “Xenogeneic thymokidney and thymic tissue transplantation in a pig-to-baboon model: I. evidence for pig-specific T-cell unresponsiveness,” Transplantation, vol. 75, no. 10, pp. 1615–1624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Gollackner, N. J. Mueller, S. Houser et al., “Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation,” Transplantation, vol. 75, no. 11, pp. 1841–1847, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Knosalla, B. Gollackner, L. Bühler et al., “Correlation of biochemical and hematological changes with graft failure following pig heart and kidney transplantation in baboons,” American Journal of Transplantation, vol. 3, no. 12, pp. 1510–1519, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Shimizu, K. Yamada, S. Yamamoto et al., “Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2732–2745, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. A. D. Griesemer, A. Hirakata, A. Shimizu et al., “Results of gal-knockout porcine thymokidney xenografts,” American Journal of Transplantation, vol. 9, no. 12, pp. 2669–2678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. C. C. Lin, M. Ezzelarab, R. Shapiro et al., “Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation,” American Journal of Transplantation, vol. 10, no. 7, pp. 1556–1568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Nishimura, J. Scalea, Z. Wang et al., “First experience with the use of a recombinant CD3 immunotoxin as induction therapy in pig-to-primate xenotransplantation: the effect of T-cell depletion on outcome,” Transplantation, vol. 92, no. 6, pp. 641–647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Kim, C. Schuetz, N. Elias et al., “Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons,” Xenotransplantation, vol. 19, no. 4, pp. 256–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. N. Navarro-Alvarez, J. A. Shah, A. Zhu et al., “The effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation,” American Journal of Transplantation, vol. 16, no. 6, pp. 1715–1725, 2016. View at Publisher · View at Google Scholar · View at Scopus
  107. B. J. Hering, M. Wijkstrom, M. L. Graham et al., “Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates,” Nature Medicine, vol. 12, no. 3, pp. 301–303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Cardona, G. S. Korbutt, Z. Milas et al., “Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways,” Nature Medicine, vol. 12, no. 3, pp. 304–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. P. P. Rood, R. Bottino, A. N. Balamurugan et al., “Reduction of early graft loss after intraportal porcine islet transplantation in monkeys,” Transplantation, vol. 83, no. 2, pp. 202–210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Casu, R. Bottino, A. N. Balamurugan et al., “Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: implications for translation into clinical practice,” Diabetologia, vol. 51, no. 1, pp. 120–129, 2008. View at Publisher · View at Google Scholar
  111. R. Bottino, M. Wijkstrom, D. J. van der Windt et al., “Pig-to-monkey islet xenotransplantation using multi-transgenic pigs,” American Journal of Transplantation, vol. 14, no. 10, pp. 2275–2287, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. J. S. Shin, J. M. Kim, J. S. Kim et al., “Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets,” American Journal of Transplantation, vol. 15, no. 11, pp. 2837–2850, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Hecht, S. Eventov-Friedman, C. Rosen et al., “Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 21, pp. 8659–8664, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. M. L. Graham and H. J. Schuurman, “The usefulness and limitations of the diabetic macaque model in evaluating long-term porcine islet xenograft survival,” Xenotransplantation, vol. 20, no. 1, pp. 5–17, 2013. View at Publisher · View at Google Scholar · View at Scopus